Author
Listed:
- Sarah A. Best
(The Walter and Eliza Hall Institute of Medical Research
The University of Melbourne)
- Sheryl Ding
(The Walter and Eliza Hall Institute of Medical Research
The University of Melbourne)
- Ariena Kersbergen
(The Walter and Eliza Hall Institute of Medical Research)
- Xueyi Dong
(The University of Melbourne
The Walter and Eliza Hall Institute of Medical Research)
- Ji-Ying Song
(The Netherlands Cancer Institute)
- Yi Xie
(The Walter and Eliza Hall Institute of Medical Research
Fudan University)
- Boris Reljic
(The University of Melbourne)
- Kaiming Li
(The Walter and Eliza Hall Institute of Medical Research
Nanjing University)
- James E. Vince
(The University of Melbourne
The Walter and Eliza Hall Institute of Medical Research)
- Vivek Rathi
(The University of Melbourne)
- Gavin M. Wright
(The University of Melbourne)
- Matthew E. Ritchie
(The Walter and Eliza Hall Institute of Medical Research
The University of Melbourne)
- Kate D. Sutherland
(The Walter and Eliza Hall Institute of Medical Research
The University of Melbourne)
Abstract
The KRAS oncoprotein, a critical driver in 33% of lung adenocarcinoma (LUAD), has remained an elusive clinical target due to its perceived undruggable nature. The identification of dependencies borne through common co-occurring mutations are sought to more effectively target KRAS-mutant lung cancer. Approximately 20% of KRAS-mutant LUAD carry loss-of-function mutations in KEAP1, a negative regulator of the antioxidant response transcription factor NFE2L2/NRF2. We demonstrate that Keap1-deficient KrasG12D lung tumors arise from a bronchiolar cell-of-origin, lacking pro-tumorigenic macrophages observed in tumors originating from alveolar cells. Keap1 loss activates the pentose phosphate pathway, inhibition of which, using 6-AN, abrogated tumor growth. These studies highlight alternative therapeutic approaches to specifically target this unique subset of KRAS-mutant LUAD cancers.
Suggested Citation
Sarah A. Best & Sheryl Ding & Ariena Kersbergen & Xueyi Dong & Ji-Ying Song & Yi Xie & Boris Reljic & Kaiming Li & James E. Vince & Vivek Rathi & Gavin M. Wright & Matthew E. Ritchie & Kate D. Sutherl, 2019.
"Distinct initiating events underpin the immune and metabolic heterogeneity of KRAS-mutant lung adenocarcinoma,"
Nature Communications, Nature, vol. 10(1), pages 1-14, December.
Handle:
RePEc:nat:natcom:v:10:y:2019:i:1:d:10.1038_s41467-019-12164-y
DOI: 10.1038/s41467-019-12164-y
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:10:y:2019:i:1:d:10.1038_s41467-019-12164-y. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.